Forbes Finance Council Member
Working at the intersection of brokerage growth, fintech, regulation and regional expansion, with more than 15 years of leadership experience across MENA, CIS, Europe and emerging markets.
Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.
By Amy Feldman
Palantir cofounder Joe Lonsdale is investing in an animal testing company that aims to secure a national supply chain of monkeys for biomedical testing.
By Iain Martin, Senior Editor
Palm Beach has attracted tremendous wealth and investment capital. Can it become a thriving technology hub? Exploring startups, venture capital, and innovation.
By Ben Topor, Contributor
In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.
By Amy Feldman, Senior Editor
As AI valuations cross billions, the business model question becomes more critical than ever. The lofty valuations, while justified by investors, raise doubts as well.
By Sanjit Singh Dang, PhD, Contributor
Our fall guide to the books, podcasts and newsletters offering fresh perspectives on the people, technologies and forces driving venture capital and AI.
By TrueBridge Capital, Contributor
Menlo Ventures investor Venky Ganesan says price has replaced fundamentals as the signal in AI. His fix: size your positions like a public market investor.
By Josipa Majic Predin, Contributor
VCs need extraordinary home runs, yet even top VCs miss most of them. What the numbers reveal about VC returns – and what entrepreneurs should learn.
By Dileep Rao, Contributor
Conviction GP Mike Vernal argues AI erases switching costs and network effects. Why he thinks software splits like newspapers and what founders should do.
By Josipa Majic Predin, Contributor
TypeSafe’s Jev returns AI decisions in milliseconds for near-zero cost. Inside the $40M DCVC seed, the independent tests and how agent builders can use it now.
By Josipa Majic Predin, Contributor
Former Reddit CEO Yishan Wong says AI safety debates fail because they conflate existential risk with misuse. Why VCs are betting on both sides of his divide.
By Josipa Majic Predin, Contributor
AI agents now generate two thirds of documentation traffic. Inside the $500M bet on knowledge engineers and the Air Canada ruling every company should read.
By Josipa Majic Predin, Contributor
We live in an era where we are faced with some of the greatest challenges ever. Venture Capital is crucial here, serving as the original impact investor.
By Kjartan Rist, Contributor